Lab-grown embryo models are getting more realistic. Scientists are getting more concerned
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form laboratory-grown structures that resemble human embryos.
These embryo models are far from perfect replicas. But as labs compete to grow the best likeness, the structures are becoming increasingly complex, looking and behaving in some way as embryos would.
The structures could further the study of human development and the causes infertility. However, the dizzying pace of the research, which started little more than a decade ago, is posing ethical, legal and regulatory challenges for the field of developmental biology.
'We could have never anticipated the science would have just progressed like this. It's incredible, it's been transformative how quickly the field has moved, said Amander Clark, a professor of molecular cell and developmental biology at the University of California, Los Angeles, and the founding director of the UCLA Center for Reproductive Science, Health and Education. 'However, as these models advance, it is crucial that they are studied in a framework that balances scientific progress with ethical, legal and social considerations.'
Clark is co-chair of the International Society of Stem Cell Research (ISSCR) Embryo Models Working Group, which is now trying to update such a framework on a global scale. At issue is the question of how far researchers could go with these stem cells, given time and the right conditions. Could scientists eventually replicate an actual embryo that has a heartbeat and experiences pain, or one that could grow into a fully developed human model?
Embryo models: How realistic are they?
As current research stands, no model mimics the development of a human embryo in its entirety — nor is any model suspected of having the potential to form a fetus, the next stage in human development equivalent to week 8 or day 56 in a human pregnancy. Creating embryo models has also been a hit-and-miss process for most research groups, with only a small percentage of stem cells going on to self-organize into embryo-like structures.
However, the models do exhibit several internal features and cell types that an embryo needs to develop, such as the amnion, yolk sac and primitive streak, and that could, 'with future improvements, eventually progress toward later embryo structures including heart, brain, and other organ rudiments,' according to a June paper coauthored by Clark and published in the journal Stem Cell Reports. Similar models made with mouse cells have reached the point where the brain begins to develop and a heart forms.
Critically, the goal isn't to develop these models into viable fetuses, ultimately capable of human sentience, but to develop a useful research tool that unlocks the mysteries of how a human cell divides and reproduces to become a human body. The models also make way for experiments that can't be performed on donated embryos in a lab. However, it's possible as research advances that the distinction between a lab-grown model and a living human embryo could become blurred.
And because the models lie at the intersection of historically controversial fields — stem cell biology and embryology — the work merits closer oversight than other forms of scientific research, Clark said.
Clark and the ISSCR's Embryo Models Working Group in June recommended enhanced oversight of research involving the models. The society's guidelines, which first included guidance on embryo models in 2021, are being revised to incorporate the recommendations of the group and will be released in a few weeks.
The current ISSCR guidelines make a distinction between 'integrated embryo models' that replicate the entire embryo, and 'non-integrated models' that replicate just one part of an embryo, requiring stricter oversight of the former. The updated guidelines will instead recommend that all research involving both types of embryo models should undergo 'appropriate ethical and scientific review.'
The proposed update will also set out two red lines: The current guidance already prohibits the transfer of human embryo models into a human or animal uterus. The updated version will also advise scientists not use human embryo models to pursue ectogenesis: the development of an embryo outside the human body via the use of artificial wombs — essentially creating life from scratch.
According to Clark, the stem cell-based embryo models she and other research teams work on should be considered distinct from research on actual human embryos, usually surplus IVF embryos donated to science. Such research is tightly regulated in many countries, and banned in others, including Germany, Austria and Italy.
It makes sense, at least for now, to treat models and real embryos differently, said Emma Cave, a professor of healthcare law at Durham University in the UK who works on embryo models. She uses diamonds as an analogy: Natural diamonds and their commercially lab-grown equivalents are made from the same chemical components, but society assigns them different values. She cautioned there shouldn't be a rush to regulate embryo models too quickly in case it shuts down promising research.
'We are at an early stage in their development, where it could be that in 5, 10, 15, 20 years, that they could look very like a human embryo, or it might be they never get to that stage,' she said.
Embryo Scientists
Scientists look at a model of an early-stage human embryo created by Israeli scientists at the Weizmann Institute of Science in Rehovot, Israel, September 7, 2023. (Amir Cohen/Reuters via CNN Newsource)
A 'Turing test' for embryo models
As the scientific research unfolds, oversight of embryo models is taking different shapes in different jurisdictions. Australia has taken the strictest approach. It includes embryo models within the regulatory framework that governs the use of human embryos, requiring a special permit for research.
The Netherlands in 2023 similarly proposed treating 'non-conventional embryos' the same as human embryos in the eyes of the law. The proposal is still under discussion, according to the Health Council of the Netherlands.
Researchers in the United Kingdom released a voluntary code of conduct in 2024, and Japan has also issued new guidelines governing research in the field.
In the United States, embryo models aren't covered by any specific legal framework, and research proposals are considered by individual institutions and funding bodies, Clark noted. The National Institutes of Health said in 2021 that it would consider applications for public funding of research into embryo models on a case-by-case basis and monitor developments to understand the capabilities of these models.
Few other countries, however, appear poised to adopt specific legislation on embryo models, making the guidelines issued by the ISSCR a 'highly influential' reference for researchers around the world, according to the Nuffield Council on Bioethics, a London-based organization that advises on ethical issues in biomedicine.
The council said in a November 2024 report that international guidelines were key to avoid 'research being carried out that does not meet high ethical and scientific standards; this in turn could impact on the national public perception of risk, leading to a more risk-averse approach that hinders responsible scientific development.'
Clark said the ISSCR's updated voluntary guidelines would help scientific funding bodies around the world better evaluate applications and publishers of research understand whether work was performed in an ethically responsible way, particularly in places where the law or other guidelines don't take embryo models into account.
The future challenge for regulators is to understand when and whether an embryo model would be functionally the same as a human embryo and therefore potentially afforded the same or similar protection as those surrounding human embryos, said Naomi Moris, group leader at The Francis Crick Institute's developmental models laboratory. The only definitive test would be to transfer the model into the uterus of a surrogate, a move that's forbidden by current bioethical standards.
However, Moris is among a group of researchers that has proposed to two tipping points or 'Turing tests' — inspired by computer scientist Alan Turing's way of determining whether machines can think like humans — to evaluate when distinctions between a lab-gown model and a human embryo would disappear.
'These things are not embryos at the moment, they clearly don't have the same capacity as an embryo does. But how would we know ahead of time that we were approaching that?' Moris said. 'That was the logic behind it. What metrics would we use as a kind of proxy for the potential of an embryo model that might then suggest that it was at least approaching the same sorts of equivalency as an embryo.'
The first test would measure whether the models can be consistently produced and faithfully develop over a given period as normal embryos would. The second test would assess when animal stem cell embryo models — particularly animals closest to humans such as monkeys — show the potential to form living and fertile animals when transferred into surrogate animal wombs, thus suggesting that the same outcome would in theory be possible for human embryo models.
That hasn't happened yet, but Chinese researchers in 2023 created embryo models from the stem cells of macaque monkeys that when implanted in a surrogate monkey triggered signs of early pregnancy.
Embryo ethics: A delicate dance
Proponents of the technology say the models offer an equally, and possibly more, useful, ethical alternative to research on scarce and precious human embryos. The models have the potential to be produced at scale in a lab to screen drugs for embryo toxicology, a impactful application given that pregnant women have often been excluded from drug trials because of safety concerns.
Lab based embryo models
A 3D-printed replica of a human embryo model on display as part of an exhibit by The Francis Crick Institute at the Royal Society's Summer Science Exhibition in London earlier this month. The replica is about 500 times bigger than the actual embryo model, which was 0.3 millimeters. (Stephen Potvin via CNN Newsource)
Yet, the potential for these models to be used in the creation of life has been cause for worry among bioethicists. 'There are commercial and other groups raising the possibility of building an embryo in vitro and combining different bioengineering approaches to bring such an entity to viability,' according to the June paper coauthored by Clark and other members of the ISSCR's embryo model working group.
'Currently the practice of bringing an SCBEM (stem cell-based embryo model) to viability is considered unsafe and unethical and should not be pursued,' the study noted.
Cave said ectogenesis may sound like the realm of science fiction, but it isn't impossible. As embryo models continue to be developed, and separate research is advancing into artificial wombs, the two technologies could meet, Cave said.
The challenge, she added, is recognizing the value of these research paths but at the same time preventing misuse.
Jun Wu, an associate professor at the Department of Molecular Biology at the University of Texas Southwestern is one of a number of stem cell biologists involved in the field. He agreed that ectogenesis should be off the table but explained that researchers developing embryo models must engage in a delicate dance: To the unlock the mysteries of the human embryo, models have to resemble embryos closely enough to offer real insight but they must not resemble them so closely that they risk being viewed as viable.
'The big black box' — and a breakthrough
Magdalena Zernicka-Goetz, the Bren professor of biology and biological engineering at Caltech, said she welcomed the new guidelines.
She announced in 2023 that her team had succeeded in a world first: growing embryo-like models to a stage resembling 14-day-old embryos. Later the same year, Jacob Hanna, a professor of stem cell biology and embryology at the Weizmann Institute of Science in Israel, said his team had gone a step further with a model derived from skin cells that showed all the cell types that are essential for an embryo's development — including the precursor of the placenta.
Together the work represented a breakthrough for the models' potential use in research on pregnancy loss: At 14 days the human embryo has begun to attach to the lining of the uterus, a process known as implantation. Many miscarriages occur around this stage, Zernicka-Geotz said.
Lab research on human embryos beyond 14 days, including those donated from IVF treatments, is prohibited in most jurisdictions. And while some scientists do study tissue obtained from abortions, such tissue is limited because few procedures take place between week 2 and week 4 of an embryo's development.
The ability to grow an embryo model outside of a womb at this developmental stage paves the way for studies that are not possible in living human embryos.
'Far more pregnancies fail than succeed during the critical window just before, during and immediately after implantation. This is why we created in my lab the embryo-like structures from stem cells as a way to really understand this critical and so highly fragile stage of development,' Zernicka-Goetz said.
Clark agreed that embryo models could potentially be used to address infertility problems: 'Implantation. It's the big black box. Once the embryo implants in the uterus, we understand very little about the development,' Clark added.
'And if we can't study it, we don't know what we're missing.'
By Katie Hunt, CNN
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
4 hours ago
- CTV News
Six planets are hanging out in early morning skies this month. Here's how to spot them
NEW YORK — Six planets are hanging out in the sky this month in what's known as a planetary parade. Catch the spectacle while you can because it's the last one of the year. These linkups happen when several planets appear to line up in the night sky at once. Such parades are fairly common, happening around every year depending on the number of planets. At least one bright planet can be spotted on most nights, weather permitting, according to NASA. Six planets were visible in January skies and every planet of our solar system was visible in February, but not all could be spotted with the naked eye. Venus, Jupiter, Saturn and a faint Mercury are visible this month without any special equipment, and the best chances to spot them are over the next week. Uranus and Neptune can only be glimpsed through binoculars and telescopes. Jupiter and Venus made a close brush earlier this week and are still near each other in the eastern sky, 'close together like cat's eyes,' said Carolyn Sumners at the Houston Museum of Natural Science. Mercury will be at its farthest point from the sun on Tuesday morning, making it easier to spot before it disappears into the sun's glare. To catch the planets, go out in the morning shortly before sunrise and look east. Try to find Jupiter and Venus clustered together first. Saturn is off to the side and Mercury will be close to the horizon, trying to rise before the sun. 'You're looking for little tiny pinpoints of light, but they are the brightest ones,' said Justin Bartel with the Science Museum of Virginia. 'They don't really twinkle like the stars do.' Before heading out, make sure it is a clear, cloudless morning and try to get away from tall buildings that could block the view. Mercury will hide behind the sun again toward the end of the month, but a crescent moon will then join the parade. The next big planetary hangout is in February. ___ Adithi Ramakrishnan, The Associated Press The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.


CBC
4 hours ago
- CBC
Rabbits with strange horn-like growths spotted in Colorado
Social Sharing A group of rabbits in Colorado with grotesque, horn-like growths may seem straight out of a low-budget horror film, but scientists say there's no reason to be spooked — the furry creatures merely have a relatively common virus. The cottontails recently spotted in Fort Collins are infected with the mostly harmless Shope papillomavirus, which causes wart-like growths that protrude from their faces like metastasizing horns. Viral photos have inspired a fluffle of unflattering nicknames, including "Frankenstein bunnies," "demon rabbits" and "zombie rabbits." But their affliction is nothing new, with the virus inspiring ancient folklore and fuelling scientific research nearly 100 years ago. The virus likely influenced the centuries-old jackalope myth in North America, which told of a rabbit with antlers or horns, among other animal variations. The disease in rabbits also contributed to scientists' knowledge about the connection between viruses and cancer, such as the human papillomavirus, which causes cervical cancer. The virus in rabbits was named after Dr. Richard E. Shope, a professor at the Rockefeller University who discovered the disease in cottontails in the 1930s. News about the rabbit sightings in Fort Collins, 105 kilometres (65 miles) north of Denver, got attention after residents started spotting them around town and posting pictures. Kara Van Hoose, a spokesperson for Colorado Parks and Wildlife, told The Associated Press on Wednesday that the agency has been getting calls about the rabbits seen in Fort Collins. She said it's not uncommon to see infected rabbits, especially in the summer, when the fleas and ticks that spread the virus are most active. The virus can spread from rabbit to rabbit but not to other species, including humans and pets, she said. The growths resemble warts but can look like horns if they grow longer, Van Hoose said. The growths don't harm rabbits unless they grow on their eyes or mouths and interfere with eating. Rabbits' immune systems are able to fight the virus and, once they do, the growths will disappear, she said.


National Post
6 hours ago
- National Post
Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results
Article content Article content Q2 marked a critical inflection point in EB-003 development with mechanism confirmation, therapeutic opportunity expansion, IND-enabling progress, and continued strengthening of Enveric's differentiated neuroplastogen pipeline and IP platform. Q2 financial results were consistent with overall performance over the previous four quarters, and development costs were in line with budgeted IND-enabling activities. Article content Article content CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the second quarter ended June 30, 2025, and provided a comprehensive business update. Article content CEO Commentary Article content 'The second quarter of 2025 represented a period of focused execution across all key areas of our business, most notably with the advancement of EB-003, our lead drug candidate,' said Joseph Tucker, Ph.D., Director and CEO of Enveric. 'We disclosed important new data demonstrating that EB-003 engages both the 5-HT₂ A and 5-HT₁ B receptors through a dual mechanism of action. We believe this receptor pairing forms the foundation for a novel pharmacological class. With this discovery, we believe EB-003 has emerged as a first-in-class therapeutic candidate with a dual mechanism that represents a unique therapeutic target with real-world clinical utility.' Article content 'This new pharmacological class is defined by agonism at the 5-HT₁ B receptor, which modulates affective tone, impulsivity, and reward pathways, as well as concurrent partial agonism at the 5-HT₂ A receptor, which supports cortical neuroplasticity. We believe this novel and unique profile has the potential to promote adaptive rewiring of brain circuits (i.e. neuroplasticity) while stabilizing emotional reactivity, motivational control, and behavioral regulation (i.e., generally psychological stability). It is expected to unlock the therapeutic benefits of serotonin mediated plasticity and guide those effects toward outcomes that are durable, broadly accessible, and clinically relevant for real-world patient populations.' Article content 'By targeting this specific set of neural receptors, the intent is for EB-003 to recalibrate emotional reactivity, facilitate extinction of maladaptive fear responses, and restore motivational tone. These are mechanisms believed to support lasting recovery in conditions such as post-traumatic stress disorder (PTSD), treatment resistant depression, and generalized anxiety. The addition of 5-HT₁ B agonism is intended to guide plasticity into emotionally grounded outcomes; thus, the designation of EB-003 as a first-in-class drug candidate.' Article content 'With these advances, EB-003 continues to differentiate itself in a competitive neuropsychiatric drug development landscape, with pre-IND test data for EB-003 pointing to a fast acting, durable, and non-hallucinogenic treatment for serious mental health conditions where currently available therapies are either too slow, poorly tolerated, or not very effective.' 'Beyond EB-003, we made meaningful progress in expanding our intellectual property portfolio, which remains a foundational pillar of our strategy. During the second quarter, we secured an additional patent grant in our EVM-301 portfolio and patent allowances across multiple distinct chemical classes in our EVM-301 and EVM-401 portfolios, further reinforcing Enveric's leadership in the discovery of rationally designed neuroplastogens. With a growing portfolio of issued patents and new filings underway, we are seeking to build a durable, competitive moat around our lead assets and future pipeline candidates.' Article content 'Looking ahead to the remainder of 2025 and into 2026, we remain sharply focused on filing an Investigational New Drug (IND) application for EB-003 and preparing for its first-in-human study. We also continue to benefit from ongoing dialogue and growing interest from established pharmaceutical companies with a strategic focus in neuropsychiatry, which underscores the increasing relevance of our platform in a field that has lacked innovation for far too long.' Article content Second Quarter and Recent Corporate Highlights Article content Revealed EB-003's Dual Mechanism of Action: Enveric confirmed that EB-003, its lead compound, engages both 5-HT₂ A (partial agonist) and 5-HT₁ B (agonist) receptors, a dual mechanism not previously reported in clinical-stage neuropsychiatric drug candidates. This unique pharmacology forms the basis of a new pharmacological class designed to promote therapeutic neuroplasticity, emotional recalibration, and enhanced control over affective and behavioral responses without the need for hallucinogenic intervention. Progressed Toward IND Submission: IND-enabling studies for EB-003 remain on track, with submission to the U.S. FDA anticipated in early 2026. Enveric continues to generate data supporting EB-003's safety, tolerability, and pharmacokinetic profile, including results supporting extended, repeat-dose oral use. Expanded Therapeutic Opportunity: PTSD: In a validated preclinical model, EB-003 produced rapid extinction of contextual fear responses following a single administration. Chronic Depression: Mice treated with EB-003 exhibited a statistically significant reduction in behavioral despair (p < 0.01) in the forced swim test, a standard model of antidepressant efficacy. Dosing Profile: Supporting data indicate EB-003 is well tolerated with daily oral administration, distinguishing it from hallucinogenic agents that require intensive supervision and infrequent dosing. Article content Intellectual Property Expansion Article content Broadened Patent Portfolio Across Two Molecular Classes: Filed a new patent application covering a novel chemical structure with potential relevance in neurodegenerative and cognitive indications. Received a Notice of Allowance from the U.S. Patent and Trademark Office for a second mescaline-derivative analogs patent, reinforcing Enveric's leadership in modifying classical psychedelic frameworks into non-hallucinogenic, drug-like structures. Secured a composition of matter patent on N-Substituted Tryptamine Derivatives, extending the Company's IP coverage of EVM-301 molecules into this new class of drugs and the serotonergic field. Article content Second Quarter 2025 Financial Results Article content Net loss attributable to common stockholders was $2.5 million for the quarter ending June 30, 2025, or $0.97 per share, compared to a net loss of $1.9 million, or $3.72 per share, for the same period in 2024. The net loss for the quarter included approximately $0.2 million in non-cash expenses related to stock-based compensation and other non-cash charges. As of June 30, 2025, Enveric had cash and cash equivalents of $2.8 million. The Company continues to fund its operations through the use of various financing tools. The Company has raised net proceeds of $4.9M for the six months ended June 30, 2025. Article content About Enveric Biosciences Article content Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric's lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT₂ A and 5-HT₁ B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience. For more information, please visit Article content Forward-Looking Statements Article content This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. Article content A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Article content Article content Article content Article content Contacts Article content Investor Relations Tiberend Strategic Advisors, Inc. David Irish (231) 632-0002 dirish@ Media Relations Tiberend Strategic Advisors, Inc. Casey McDonald (646) 577-8520 cmcdonald@ Article content